so for the less engaged people like me....
is the significance of this announcement that - it reaffirms the aml efficacy with modern data thereby derisking a floor value for bisantrene based on AML treatment. less than a potential fto / cardio protection type value but also easuer to understand and value.
we still have the potential for a mega validation on that but now if that doesn't work out the fallback aml case is derisked.
would taht be a fair summary?
Ann: Bisantrene shows potent anticancer activity in AML models, page-70
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
-0.095(5.44%) |
Mkt cap ! $281.0M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.78 | $1.62 | $285.9K | 170.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16759 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 12047 | 1 |
View Market Depth
| Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |